Announcements Trials

Browse Landscape

Phase

Phase 2 15 Phase 1/2 9 Phase 1 3 Phase EARLY_PHASE1 2 Phase 3 1

Status

Completed 31 Recruiting 25 Active not recruiting 20 Terminated 8 Not yet recruiting 5 Unknown 4 Withdrawn 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 22 Carboplatin 15 Radiotherapy 13 Paclitaxel 11 Gemcitabine 10 Rituximab 9 Fluorouracil 9 Drug Therapy 6 Dexamethasone 5 Cyclophosphamide 5 Capecitabine 5 Bevacizumab 5 Vinorelbine 4 Pemetrexed 4 Nivolumab 4 Methotrexate 4 Etoposide 4 Docetaxel 4 Bendamustine Hydrochloride 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 fludarabine 3 Vincristine 3 Trastuzumab 3 Surgical Procedures, Operative 3 Standard of Care 3 Prednisone 3 Oxaliplatin 3 Lenalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × 130-nm albumin-bound paclitaxel × Clear all

NCT05791097 2023-07-24

AdvanTIG-306

Novartis

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡